Salvage endoscopic submucosal dissection for esophageal adenocarcinoma arising during radiofrequency ablation

Sarra Oumrani*a, Maximilien Barret*ab, Frédéric Beuvonbh, Sarah Leblanc*, Stanislas Chaussadeab, Frédéric Prat*ab
Cochin Hospital, Assistance Publique-Hôpitaux de Paris; Paris-Descartes University; Cochin Hospital, Paris, France
*These authors contributed equally to the manuscript

Abstract

Radiofrequency ablation is a recommended treatment option for residual Barrett's esophagus after endoscopic resection of a visible lesion. We herein report 3 cases of esophageal adenocarcinoma arising during the course of radiofrequency ablation, all of which were successfully resected by endoscopic submucosal dissection. Partial or suboptimal response to radiofrequency ablation or early recurrence of Barrett’s mucosa after radiofrequency ablation should raise suspicion for adenocarcinoma and lead to consideration of en bloc resection by endoscopic submucosal dissection.

Keywords Barrett’s esophagus, adenocarcinoma, radiofrequency, endoscopic submucosal dissection

Ann Gastroenterol 2018; 31 (4): 522-524

Introduction

Barrett’s esophagus (BE) is defined by the replacement of the normal squamous epithelium of the tubular esophagus by intestinal metaplasia [1]. The risk of progression of BE to adenocarcinoma depends on the presence of dysplasia, ranging from 0.2-0.5% per year for non-dysplastic BE to 7% per year for patients with high-grade dysplasia [1]. A two-step treatment paradigm, starting with the endoscopic resection of any visible abnormality on the Barrett’s segment, followed by the ablation of the residual BE with several sessions of radiofrequency ablation (RFA), has emerged as the standard of care for dysplastic BE [1,2]. This treatment protocol, typically spanning over 6-9 months, requires 2-3 RFA sessions and yielded complete remission of dysplasia and complete remission of intestinal metaplasia in 92% and 87% of cases, respectively, at two years in a recent multicenter international trial [2]. We report 3 cases of neoplastic progression occurring during treatment by RFA.

Case 1

The first case was a 71-year-old male patient with a recently diagnosed C5M6 BE, who underwent endoscopic submucosal dissection (ESD) of a 4 cm Barrett’s segment for a nodular, Paris 0-IIa, 15 mm large lesion. Histopathology showed a pT1a/m3 adenocarcinoma with histologically complete (R0) resection and all lateral margins in squamous mucosa (Fig. 2C,D).

Case 2

A 50-year-old male patient, previously treated over two years by repeated endoscopic mucosal resection (EMR) for a C5M10 BE with high-grade dysplasia, subsequently underwent a total of...
4 RFA sessions at 2-month intervals. High-definition endoscopy and biopsies did not reveal any lesion suspicious for carcinoma, either before or during RFA. At the 3-month follow-up endoscopy after the fourth RFA session, a residual C2M4 nodular BE was found (Fig. 3A,B,C). Therefore, wide resection by ESD of the nodular part and most of the residual Barrett’s segment was performed, including two thirds of the esophageal circumference over 6 cm in length. Pathology revealed a 1.2 cm well differentiated intramucosal T1a/m2 adenocarcinoma, partially covered by neosquamous mucosa with histologically complete (R0) and curative resection. At 6-month follow up, a C0M1 BE was seen with non-dysplastic intestinal metaplasia on biopsies, unchanged at 12 months under treatment with a proton pump inhibitor.

Case 3

A 76-year-old male patient underwent EMR of a visible lesion bearing high-grade dysplasia arising on a C2M10 BE. High-definition endoscopy and biopsies of the residual C2M9 BE found no suspicious residual lesion, and the patient was scheduled for RFA eradication of the residual BE. After one RFA treatment session (Fig. 4A), the second session scheduled 2 months later was canceled, because two suspicious nodules had appeared on the residual BE (Fig. 4B,C). Adenocarcinoma was found on biopsies. An ESD was performed to remove two thirds of the esophageal circumference and the complete length of the Barrett’s segment. Pathology showed well differentiated intramucosal T1a/m3 adenocarcinoma with histologically complete resection and no lymphovascular involvement (R0 curative resection). Follow-up was discontinued when the patient died from a primary pulmonary adenocarcinoma 11 months later.
Discussion

This report describes 3 patients who developed early adenocarcinoma during or shortly after completing RFA therapy and were ultimately cured by rescue endoscopic submucosal dissection. Leaving in place residual Barrett's mucosa after endoscopic resection of a visible, neoplastic lesion leads to the occurrence of metachronous neoplasia in up to 21.5% of patients at 5 years [3]. Indeed, surgical series have reported the presence of multifocal neoplastic foci in up to 30% of patients operated for an early Barrett's cancer [4], some of which might be overlooked by the endoscopist. For these reasons, and given its good efficacy and safety profile, RFA is the recommended therapeutic modality to eradicate residual BE after endoscopic resection [1].

After a median of 3 ablation sessions, RFA allows for complete eradication of intestinal metaplasia and neoplasia in up to 90% and 94% of patients at 5 years, respectively [2]. Progression to adenocarcinoma during treatment has been reported to occur in 0.8-1.5% [2,5]. Haidry et al reported salvage endoscopic resection using RFA for visible lesions arising during RFA treatment in 5-6% of patients, but did not provide details on the lesions resected and the outcomes of this specific patient group [6]. Given the likelihood of invasive carcinoma, the pretreated esophageal mucosa with more difficult submucosal lifting or lesion suctioning, and the advantages of a large en bloc resection of the residual BE, we consider ESD should be preferred over EMR: all the more recent prospective studies have demonstrated the safety of ESD for Barrett's neoplasia, but also its superiority over EMR in terms of complete remission of dysplasia [7-9]. Although the current guidelines of the European Society of Gastrointestinal Endoscopy, released in 2015 [10], still favor EMR in most cases, these recent results should prompt an increase in the use of ESD in the treatment of early Barrett's neoplasia in treatment-naive and in pretreated patients in the near future.

The risk of neoplastic progression or recurrence during RFA treatment is low, but justifies a meticulous endoscopic follow up before proceeding with further ablation sessions. When a visible lesion is detected, we suggest RFA should be withheld and en bloc ESD be considered a priority.

References

1. Shaheen NJ, Falk GW, Iyer PG, Gerson LB; American College of Gastroenterology. ACG Clinical Guideline: Diagnosis and management of Barrett's esophagus. Am J Gastroenterol 2016;111:30-50.
2. Phoa KN, Pouw RE, Bisschops R, et al. Multimodality endoscopic eradication for neoplastic Barrett oesophagus: results of an European multicentre study (EURO-II). Gut 2016;65:555-562.
3. Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut 2008;57:1200-1206.
4. Altorki NK, Lee PC, Liss Y, et al. Multifocal neoplasia and nodal metastases in T1 esophageal carcinoma: implications for endoscopic treatment. Ann Surg 2008;247:434-439.
5. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 2009;360:2277-2288.
6. Haidry RJ, Lipman G, Banks MR, et al. Comparing outcome of radiofrequency ablation in Barrett's with high grade dysplasia and intramucosal carcinoma: a prospective multicenter UK registry. Endoscopy 2015;47:980-987.
7. Barret M, Cao DT, Beuvon F, et al. Endoscopic submucosal dissection for early Barrett's neoplasia. United European Gastroenterol J 2016;4:207-215.
8. Subramaniam S, Chedgy F, Longcroft-Wheaton G, et al. Complex early Barrett's neoplasia at 3 Western centers: European Barrett's Endoscopic Submucosal Dissection Trial (E-BEST). Gastrointest Endosc 2017;86:608-618.
9. Subramaniam S, Kandiah K, Chedgy F, Meredith P, Longcroft-Wheaton G, Bhandari P. The safety and efficacy of radiofrequency ablation following endoscopic submucosal dissection for Barrett's neoplasia. Dis Esophagus 2018;31.
10. Pimentel-Nunes P, Dinis-Ribeiro M, Ponchon T, et al. Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2015;47:829-854.